Press Releases

Webcast
Q4 2017 Geron Earnings Conference Call
Mar 19, 2018 at 8:30 AM EDT
Webcast Presentation

Q4 2017 Geron Earnings Conference Call
Mar 19, 2018 at 8:30 AM EDT
Webcast
Geron at 17th Annual Needham Healthcare Conference
Mar 27, 2018 at 4:00 PM EDT
Webcast Presentation

Geron at 17th Annual Needham Healthcare Conference
Mar 27, 2018 at 4:00 PM EDT
Date Title and Summary  
Toggle Summary Geron to Restate Financial Results of Prior Periods
No Impact on Reported Revenues, Operating Expenses, Total Assets or Cash Position MENLO PARK, Calif., March 9, 2007 – Geron Corporation (Nasdaq: GERN) today announced that the company will restate its financial statements for the 2005, 2004 and 2003 fiscal years as well as its quarterly financial
Toggle Summary Geron Corporation Announces Exercise Of Warrants for $15.0 Million of Proceeds
MENLO PARK, Calif., Feb. 27, 2007 – Geron Corporation (Nasdaq: GERN) today announced the exercise of warrants to purchase 1,875,000 shares of common stock at $8.00 per share for gross proceeds of $15.0 million. The exercised warrants were issued to institutional investors in connection with the
Toggle Summary Unique Structure of Geron´s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity in Lung Cancer Cells
MENLO PARK, Calif., Feb. 15, 2007 – Geron Corporation (Nasdaq: GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti–tumor and anti–metastatic activity. Published in Cancer Research (2007; 67: 1121–29), the studies
Toggle Summary Geron Corporation to Present at BIO CEO & Investor Conference
MENLO PARK, Calif., Feb. 9, 2007 – Geron Corporation (Nasdaq: GERN) will present an update of the company’s product development programs at 1:15 p.m. ET on Monday, Feb. 12, 2007, at the BIO CEO & Investor Conference in New York City. The update of Geron’s portfolio of telomerase–based anti–cancer
Toggle Summary Studies Show Geron´s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors
Findings Published in Stem Cells and Development Indicate GRNOPC1 Promotes Survival and Regeneration of Neurons Damaged During Spinal Cord Injury MENLO PARK, Calif., Jan. 17, 2007 – Geron Corporation (Nasdaq: GERN) today reported that studies show GRNOPC1, the company’s human embryonic stem cell